When complete heart block signals cardiac sarcoidosis

Complete heart block in a relatively young adult should prompt more than an electrical diagnosis. Although degenerative conduction disease, ischaemia, infection and inherited disorders remain important possibilities, inflammatory infiltration of the conduction system can be the first visible sign of cardiac sarcoidosis. The condition may be isolated to the heart or occur alongside pulmonary, lymph-node, skin or eye disease.

Cardiac sarcoidosis can produce atrioventricular block, ventricular tachycardia, heart failure and sudden cardiac death. Its presentation ranges from an incidental abnormality on cardiac magnetic resonance imaging to profound bradycardia requiring urgent pacing. A normal chest X-ray does not exclude it, and the absence of pulmonary symptoms should not reduce clinical suspicion.

The diagnostic challenge is especially relevant when a patient presents to an Australian emergency department or regional hospital with syncope and a high-grade AV block. Access to cardiac MRI, fluorodeoxyglucose positron emission tomography and electrophysiology expertise varies between metropolitan and rural services. Early communication with a tertiary centre can reduce delays while temporary pacing, imaging and biopsy are coordinated.

A careful diagnostic pathway also determines the safest device strategy. Permanent pacing may be essential, yet an implantable cardioverter-defibrillator can be more appropriate when there is myocardial scar, ventricular dysfunction or a meaningful risk of ventricular arrhythmia. Treatment must address both the rhythm and the underlying inflammatory disease.

Recognising the clinical pattern

Complete heart block caused by cardiac sarcoidosis may occur abruptly, with dizziness, syncope, exercise intolerance or collapse. Some patients report palpitations or chest discomfort, while others have no preceding symptoms. The ECG can show a narrow- or broad-complex escape rhythm, bundle branch block, frequent ventricular ectopy or intermittent AV block before conduction deteriorates.

Age is a useful clue, though it is not diagnostic. New high-grade AV block in a person younger than about 60 years, particularly when there is no clear coronary or structural explanation, should raise suspicion. A history of pulmonary sarcoidosis, unexplained uveitis, erythema nodosum, neuropathy or inflammatory disease adds weight. Previous episodes labelled as myocarditis or idiopathic cardiomyopathy may also represent earlier cardiac involvement.

The first assessment follows standard bradycardia and acute coronary syndrome principles. Stabilise the patient, identify reversible causes, obtain serial troponin measurements and perform echocardiography. Electrolyte disturbance, medication toxicity, thyroid disease, Lyme disease where relevant, Chagas disease in selected patients and acute ischaemia require consideration. In Australia, the initial work-up may begin with a GP, ambulance service or a regional emergency department before transfer to a metropolitan cardiac unit.

Building the diagnosis with multimodality imaging

Cardiac magnetic resonance is central because late gadolinium enhancement can reveal patchy, non-ischaemic myocardial scar in the basal septum, lateral wall or other characteristic regions. T2-based sequences may indicate active oedema, while cine imaging assesses ventricular function, aneurysm formation and wall motion. Extensive scar, particularly in the septum, can explain AV block and signals a higher risk of ventricular arrhythmia.

FDG-PET complements MRI by identifying active granulomatous inflammation. Patient preparation matters: a high-fat, low-carbohydrate diet, prolonged fasting and, in some protocols, heparin are used to suppress normal myocardial glucose uptake. Incomplete suppression can make a scan difficult to interpret. PET may also identify suitable extracardiac targets for biopsy and help assess response to immunosuppression.

A normal scan does not always end the evaluation. Imaging findings must be interpreted with the ECG, symptoms, echocardiogram and extracardiac assessment. Coronary angiography or CT coronary angiography may be needed when ischaemic disease is plausible. In Australia, referral pathways differ across states, and a patient from the bush may need coordinated appointments for MRI, PET and electrophysiology rather than several separate long-distance journeys.

Confirming sarcoidosis and excluding mimics

Tissue confirmation is valuable but can be difficult. Endomyocardial biopsy has limited sensitivity because granulomatous inflammation is often patchy. Image-guided sampling of an enlarged lymph node, lung lesion, skin lesion or salivary gland is usually more productive when extracardiac disease is present. A negative biopsy does not necessarily rule out cardiac sarcoidosis if the clinical and imaging pattern is persuasive.

The differential diagnosis includes giant-cell myocarditis, lymphocytic myocarditis, arrhythmogenic cardiomyopathy, infiltrative disorders such as amyloidosis, and genetic lamin or desmosomal disease. Tuberculosis and fungal infection deserve attention before immunosuppression, especially in people with relevant travel, migration or exposure histories. In Australia, clinicians may also need to consider regional infectious risks and the patient’s country of birth rather than relying on a single routine screening panel.

A multidisciplinary review involving cardiology, electrophysiology, imaging, respiratory medicine, rheumatology and infectious diseases can resolve uncertainty. Diagnostic criteria from professional societies vary in their use of histology, MRI, PET and clinical features. The reasoning should be documented clearly, including why treatment is being started when myocardial biopsy is negative or unavailable.

Managing inflammation and ventricular risk

Corticosteroids are commonly used when active cardiac inflammation is likely, particularly with progressive conduction disease, ventricular arrhythmia or declining ventricular function. The regimen and duration depend on disease activity, organ involvement and treatment response. Steroid-sparing agents such as methotrexate, azathioprine or mycophenolate may be considered with specialist input, especially when prolonged therapy is expected.

Immunosuppression is not a substitute for pacing or defibrillator protection. A patient can develop malignant ventricular arrhythmia from established scar even after PET activity has settled. Conversely, active inflammation may improve conduction in some cases, but recovery is unpredictable and should not be assumed when complete heart block is present.

Monitoring should include symptoms, ECGs, device data, ventricular function and selected repeat imaging. Steroid treatment requires attention to glucose, blood pressure, bone health, infection risk and vaccination status. Access to medicines through Australia’s Pharmaceutical Benefits Scheme can influence the practical choice and timing of steroid-sparing therapy, while shared-care arrangements with a GP may be needed for long-term surveillance.

Choosing pacing and defibrillator therapy

Urgent temporary pacing may be required for haemodynamic instability, recurrent syncope or a slow escape rhythm. Once the diagnosis is being evaluated, permanent device implantation should not be postponed simply to wait for a response to corticosteroids. High-grade AV block in cardiac sarcoidosis carries an unpredictable risk of recurrent block and sudden death.

An ICD with pacing capability is often favoured over a pacemaker alone when there is sustained ventricular tachycardia, prior cardiac arrest, significant LV systolic dysfunction, extensive late gadolinium enhancement, inducible ventricular tachycardia or another established high-risk feature. The decision is individualised because ICD implantation carries infection, lead, inappropriate-shock and psychological burdens. Age, comorbidity and patient priorities remain relevant.

A dual-chamber pacemaker may be reasonable when the likelihood of ventricular arrhythmia is low and ventricular function is preserved, but the threshold for ICD therapy is commonly lower in confirmed cardiac sarcoidosis. If a high pacing burden is expected in a patient with reduced ejection fraction or dyssynchrony, cardiac resynchronisation therapy may be appropriate. A subcutaneous ICD cannot provide reliable bradycardia pacing, so it is generally unsuitable for complete heart block unless a separate pacing solution is used.

Device programming should account for intermittent AV conduction, atrial arrhythmias and ventricular tachycardia detection. Remote monitoring is particularly valuable for patients living far from a pacing clinic. Australian electrophysiology services can arrange follow-up through metropolitan clinics, regional outreach and remote platforms, although connectivity and travel distance need to be considered at discharge.

Follow-up across the Australian health system

Follow-up is lifelong because inflammation, scar and electrical instability can evolve at different rates. Patients need education about syncope, sustained palpitations, inappropriate shocks, infection signs and worsening breathlessness. Driving restrictions, employment involving heavy machinery and sport participation should be discussed according to Australian and state or territory requirements.

Care coordination is often the difference between a workable plan and fragmented treatment. A patient referred from a regional centre to The Alfred, Royal Melbourne Hospital, Royal Prince Alfred Hospital, Royal Brisbane and Women’s Hospital, or a Western Australian tertiary service may require a written plan covering imaging, immunosuppression, device checks and emergency contacts. Naming the responsible clinician and the next review date helps prevent gaps after discharge.

Specialist teams can use device electrograms, ambulatory monitoring and repeat echocardiography to detect ventricular arrhythmia or declining function before symptoms become severe. MRI surveillance must be planned around the implanted system, using an MRI-conditional device and an experienced protocol. PET is most useful when the result will change treatment rather than as an automatic repeated test.

Clinicians and trainees can follow emerging evidence through arrhythmia research, including work on cardiac imaging, ablation, device therapy and inflammatory cardiomyopathy. Peer-reviewed guidance is especially useful because evidence for cardiac sarcoidosis is drawn largely from observational cohorts, registry data and expert consensus rather than large randomised trials.

A presentation with complete heart block should therefore trigger urgent stabilisation, a search for reversible causes and early assessment for inflammatory or infiltrative myocardial disease. Combining ECG findings with MRI, FDG-PET, extracardiac evaluation and careful risk stratification allows the team to select pacing, ICD or resynchronisation therapy with greater confidence.

For clinicians, the practical priority is a documented multidisciplinary pathway: identify active inflammation, protect against bradycardia and sudden death, treat systemic disease, and arrange durable follow-up. For patients and families, clear explanations about device function, immunosuppression and warning symptoms support safer care well beyond the initial hospital admission.